SG11202110036RA - Method of making lipid-encapsulated rna nanoparticles - Google Patents
Method of making lipid-encapsulated rna nanoparticlesInfo
- Publication number
- SG11202110036RA SG11202110036RA SG11202110036RA SG11202110036RA SG11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA
- Authority
- SG
- Singapore
- Prior art keywords
- rna nanoparticles
- encapsulated rna
- making lipid
- lipid
- making
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962820496P | 2019-03-19 | 2019-03-19 | |
PCT/US2020/023442 WO2020191103A1 (en) | 2019-03-19 | 2020-03-18 | Method of making lipid-encapsulated rna nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110036RA true SG11202110036RA (en) | 2021-10-28 |
Family
ID=72515073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110036RA SG11202110036RA (en) | 2019-03-19 | 2020-03-18 | Method of making lipid-encapsulated rna nanoparticles |
Country Status (11)
Country | Link |
---|---|
US (2) | US11737979B2 (en) |
EP (1) | EP3942050A4 (en) |
JP (1) | JP2022525540A (en) |
KR (1) | KR20220018960A (en) |
CN (1) | CN113840926A (en) |
AU (1) | AU2020241756A1 (en) |
BR (1) | BR112021018526A2 (en) |
CA (1) | CA3133858A1 (en) |
IL (1) | IL286424A (en) |
SG (1) | SG11202110036RA (en) |
WO (1) | WO2020191103A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE059127T2 (en) | 2015-10-22 | 2022-10-28 | Modernatx Inc | Respiratory virus vaccines |
MA46766A (en) | 2016-11-11 | 2019-09-18 | Modernatx Inc | INFLUENZA VACCINE |
US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
RS65449B1 (en) | 2018-10-09 | 2024-05-31 | The Univ Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related there to |
CA3122080A1 (en) | 2018-12-06 | 2020-06-11 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
WO2021178510A1 (en) * | 2020-03-03 | 2021-09-10 | Arcturus Therapeutics, Inc. | Compositions and methods for the treatment of ornithine transcarbamylase deficiency |
CA3171219A1 (en) | 2020-03-09 | 2021-09-16 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
FI20215508A1 (en) | 2020-04-09 | 2021-10-10 | Niemelae Erik Johan | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
KR20230124927A (en) | 2020-11-25 | 2023-08-28 | 아카제라 메디신즈, 인크. | Lipid Nanoparticles for Delivery of Nucleic Acids, and Related Methods of Use |
CN112999360B (en) * | 2021-04-02 | 2023-01-06 | 四川大学 | Use of DMP nanoparticles in mRNA delivery |
WO2023014649A1 (en) * | 2021-08-02 | 2023-02-09 | Modernatx, Inc. | Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment |
CA3237904A1 (en) * | 2021-11-11 | 2023-05-19 | Arcturus Therapeutics, Inc. | Ionizable cationic lipids for rna delivery |
CN114471217A (en) * | 2022-04-02 | 2022-05-13 | 深圳市瑞吉生物科技有限公司 | Convection mixing device and method for liposome synthesis |
WO2024030369A1 (en) * | 2022-08-01 | 2024-02-08 | Modernatx, Inc. | Extraction-less reverse phase (rp) chromatography for mrna purity assessment |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4895452A (en) | 1988-03-03 | 1990-01-23 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
DE60017406T2 (en) | 1999-07-15 | 2005-09-29 | Inex Pharmaceuticals Corp., Burnaby | PROCESS FOR PREPARING LIPID-CAPTAIDED THERAPEUTIC AGENTS |
DK1519714T3 (en) * | 2002-06-28 | 2011-01-31 | Protiva Biotherapeutics Inc | Method and apparatus for preparing liposomes |
US9005654B2 (en) * | 2005-07-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
US20120021042A1 (en) | 2005-09-15 | 2012-01-26 | Steffen Panzner | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances |
SG172257A1 (en) | 2008-12-17 | 2011-07-28 | Oncothyreon Inc | Method of making small liposomes |
WO2010148013A2 (en) * | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Lipid formulated dsrna targeting the pcsk9 gene |
WO2011127255A1 (en) * | 2010-04-08 | 2011-10-13 | Merck Sharp & Dohme Corp. | Preparation of lipid nanoparticles |
US8329080B2 (en) * | 2010-04-13 | 2012-12-11 | Ricoh Company, Ltd. | Conductive composition, electrophotographic belt, image forming apparatus, and method of manufacturing conductive composition |
US9006417B2 (en) * | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
US9579338B2 (en) * | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
AU2012330819B2 (en) * | 2011-11-04 | 2017-08-31 | Nitto Denko Corporation | Single use system for sterilely producing lipid-nucleic acid particles |
EP2895146A1 (en) * | 2012-09-17 | 2015-07-22 | BIND Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
CN113813899A (en) * | 2013-03-14 | 2021-12-21 | 昭荣化学工业株式会社 | Continuous flow reactor for synthesizing nanoparticles |
CA2921161A1 (en) * | 2013-09-24 | 2015-04-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for the manufacture of lipid nanoparticles |
CN114344275A (en) | 2014-07-02 | 2022-04-15 | 川斯勒佰尔公司 | Encapsulation of messenger RNA |
ES2949172T3 (en) | 2014-07-16 | 2023-09-26 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
FI3221293T3 (en) | 2014-11-18 | 2023-04-05 | Arcturus Therapeutics Inc | Ionizable cationic lipid for rna delivery |
CN107427791B (en) | 2015-03-19 | 2021-05-14 | 康涅狄格大学 | System and method for continuous manufacture of liposomal pharmaceutical formulations |
US10526284B2 (en) * | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
WO2018119163A1 (en) | 2016-12-21 | 2018-06-28 | Payne Joseph E | Ionizable cationic lipid for rna delivery |
-
2020
- 2020-03-18 AU AU2020241756A patent/AU2020241756A1/en active Pending
- 2020-03-18 US US16/823,212 patent/US11737979B2/en active Active
- 2020-03-18 EP EP20774501.9A patent/EP3942050A4/en active Pending
- 2020-03-18 KR KR1020217033681A patent/KR20220018960A/en unknown
- 2020-03-18 SG SG11202110036RA patent/SG11202110036RA/en unknown
- 2020-03-18 WO PCT/US2020/023442 patent/WO2020191103A1/en unknown
- 2020-03-18 CA CA3133858A patent/CA3133858A1/en active Pending
- 2020-03-18 JP JP2021556498A patent/JP2022525540A/en active Pending
- 2020-03-18 CN CN202080036934.4A patent/CN113840926A/en active Pending
- 2020-03-18 BR BR112021018526A patent/BR112021018526A2/en unknown
-
2021
- 2021-09-14 IL IL286424A patent/IL286424A/en unknown
-
2023
- 2023-08-28 US US18/457,090 patent/US20230398076A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230398076A1 (en) | 2023-12-14 |
EP3942050A4 (en) | 2023-02-22 |
JP2022525540A (en) | 2022-05-17 |
AU2020241756A1 (en) | 2021-11-04 |
WO2020191103A1 (en) | 2020-09-24 |
US11737979B2 (en) | 2023-08-29 |
BR112021018526A2 (en) | 2021-11-23 |
CN113840926A (en) | 2021-12-24 |
KR20220018960A (en) | 2022-02-15 |
EP3942050A1 (en) | 2022-01-26 |
CA3133858A1 (en) | 2020-09-24 |
US20200297634A1 (en) | 2020-09-24 |
IL286424A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286424A (en) | Method of making lipid-encapsulated rna nanoparticles | |
EP3633075A4 (en) | Metal porous body and method for producing metal porous body | |
EP3463648A4 (en) | Core/shell catalyst particles and method of manufacture | |
EP3786097A4 (en) | Elevator, suspension body therefor, and method for producing same | |
EP3703886A4 (en) | Metal nanoparticles and methods of making same | |
EP3450570A4 (en) | Method for evaluating, in vivo, activity of rna-guided nuclease in high-throughput manner | |
EP3115483A4 (en) | Porous metal body and method for producing porous metal body | |
EP3405304B8 (en) | Gold nanoparticles and ecological method of production | |
EP3421610A4 (en) | METHOD FOR EVALUATING QUALITY OF miRNA DERIVED FROM BODY FLUID | |
EP3271288A4 (en) | Metal oxide particles and method of producing thereof | |
EP3307679A4 (en) | Sodium transition metal silicate and method of forming same | |
EP3765645A4 (en) | Method of aluminum-scandium alloy production | |
EP3766571A4 (en) | Hollow particles, method for producing same, and usage of same | |
GB201804594D0 (en) | Bonegraft substituteand method of manufacture | |
EP4081687A4 (en) | Method of construction | |
GB201709827D0 (en) | Method of making colloidal metal nanoparticles | |
EP3262936A4 (en) | Oily suspension composition and method for producing same | |
GB201720829D0 (en) | Aerofoil and method of manufacture | |
GB201802839D0 (en) | Method of manufacture | |
EP3347328A4 (en) | Method of forming porous ceramic particles | |
EP3467014A4 (en) | Method of producing porous body | |
GB2578185B (en) | Method of making colloidal platinum nanoparticles | |
SG11202101056RA (en) | HIGH-Mn STEEL AND METHOD OF PRODUCING SAME | |
EP3326384A4 (en) | Loudspeaker and method of its manufacture | |
EP3615085A4 (en) | Rna nanostructures, methods of making, and uses thereof |